Table 4 Comparison of sensitivities of FGFR3 mutations, methylation, and combined markers according to stage and grade
A. Diagnosis study | Primary tumor (n = 167) | |||||
Markers | Tumor stage, % (no.) | Tumor grade, % (no.) | ||||
pTa (n = 126) | pT1 (n = 25) | CIS (n = 6) | Other (n = 10) | Low (n = 100) | High (n = 67) | |
FGFR3 | ||||||
All mutations | 46.0 (58) | 28.0 (7) | 16.7 (1) | 30.0 (3) | 53.0 (53) | 23.9 (16) |
S249C | 69.0 (40) | 42.8 (3) | 62.2 (33) | 62.5 (10) | ||
Y375C | 13.8 (8) | 28.6 (2) | 33.3 (1) | 17.0 (9) | 12.5 (2) | |
R248C | 10.3 (6) | 28.6 (2) | 100 (1) | 33.3 (1) | 11.3 (6) | 25.0 (4) |
G372C | 5.2 (3) | 5.7 (3) | ||||
S249C/R248C | 1.7 (1) | 1.9 (1) | ||||
S249C/Y375C | 33.3 (1) | 1.9 (1) | ||||
Methylation | 90.5 (114) | 100 (25) | 100 (6) | 90.0 (9) | 89.0 (89) | 100 (67) |
Combined markers | 94.4 (119) | 100 (25) | 100 (6) | 90.0 (9) | 94.0 (94) | 100 (67) |
B. Follow-up study | Recurrence (n = 72) | |||||
Markers | pTa (n = 55) | pT1 (n = 11) | CIS (n = 2) | Other (n = 4) | Low (n = 47) | High (n = 25) |
FGFR3 | ||||||
All mutations | 43.6 (24) | 36.4 (4) | 50.0 (2) | 46.8 (22) | 32.0 (8) | |
S249C | 58.3 (14) | 100 (4) | 54.6 (12) | 75.0 (6) | ||
Y375C | 20.8 (5) | 13.7 (3) | 25.0 (2) | |||
R248C | 16.7 (4) | 50.0 (1) | 22.7 (5) | |||
G372C | 4.2 (1) | 4.5 (1) | ||||
S249C/R248C | 50.0 (1) | 4.5 (1) | ||||
Methylation | 89.1 (49) | 90.9 (10) | 100 (2) | 50.0 (2) | 85.1 (40) | 96.0 (24) |
Combined markers | 96.4 (53) | 100 (11) | 100 (2) | 50.0 (2) | 93.6 (44) | 96.0 (24) |